| Intense Treatment Regimen With Intravitreal Aflibercept Injection (NCT03594461) | Vitreous -Retina- Macula Consultants of New York | 2018-09-11 |
| Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial Detachment (NCT01495208) | Vitreous -Retina- Macula Consultants of New York | 2011-12-01 |
| To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD (NCT01495221) | Vitreous -Retina- Macula Consultants of New York | 2011-12-01 |
| A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study) (NCT01115556) | Vitreous -Retina- Macula Consultants of New York | 2010-05-01 |
| Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration (NCT00726466) | Vitreous -Retina- Macula Consultants of New York | 2008-03-01 |
| Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by Itself (NCT00457678) | Vitreous -Retina- Macula Consultants of New York | 2007-01-01 |
| Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (NCT00403156) | Vitreous -Retina- Macula Consultants of New York | 2006-11-01 |
| Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema (NCT00403039) | Vitreous -Retina- Macula Consultants of New York | 2006-11-01 |
| Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD (NCT00403442) | Vitreous -Retina- Macula Consultants of New York | 2006-09-01 |
| Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy (NCT00403325) | Vitreous -Retina- Macula Consultants of New York | 2006-08-01 |
| Use of Eylea for the Treatment of an Optic Nerve Hemangioma (NCT01714115) | Vitreous -Retina- Macula Consultants of New York | |